Silexion Therapeutics Ltd. (SLXN) Revenue History
Annual and quarterly revenue from 2020 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SLXN Revenue Growth
SLXN Revenue Analysis (2020–2025)
As of May 8, 2026, Silexion Therapeutics Ltd. (SLXN) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, SLXN's historical revenue data shows various trends over time.
When compared to Healthcare sector peers including SRPT (-2.2% YoY), ARWR (+14.1% YoY), and NTLA (+16.9% YoY). Compare SLXN vs SRPT →
SLXN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SLXNCurrent | $0 | - | - | - | |
 SRPT | $2.2B | -2.2% | +32.4% | -29.9% | |
 ARWR | $829M | +14.1% | +56.6% | 11.9% | |
 NTLA | $68M | +16.9% | +3.1% | -651.7% | |
 IONS | $944M | +47.5% | +5.3% | -40.5% | |
 REGN | $14.3B | +5.9% | +11.0% | 24.9% |
SLXN Historical Revenue Data (2020–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-14,000 | - | $-11,632,000 | - |
| 2024 | $0 | - | $0 | - | $-12,571,000 | - |
| 2023 | $0 | - | $0 | - | $-4,681,000 | - |
| 2022 | $0 | - | $0 | - | $-3,860,000 | - |
| 2021 | $0 | - | $0 | - | $-943,933 | - |
| 2020 | $0 | - | $0 | - | $-195,860 | - |
See SLXN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SLXN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SLXN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSLXN — Frequently Asked Questions
Quick answers to the most common questions about buying SLXN stock.
Is SLXN's revenue growth accelerating or slowing?
SLXN TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is SLXN's long-term revenue growth rate?
Silexion Therapeutics Ltd.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is SLXN's revenue distributed by segment?
SLXN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2020-2025 are available for download. Segment mix reveals concentration and diversification trends.